Significantly longer overall and progression-free survival seen among patients with limited-stage small cell lung cancer

Improved progression-free survival seen for amivantamab-lazertinib versus osimertinib as first-line treatment

Significantly longer progression-free survival, but not overall survival, seen for osimertinib in unresectable EGFR-mutation NSCLC

Findings seen among patients with resected ALK-positive non-small cell lung cancer

Significant benefit seen for neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab

Improved median overall survival and progression-free survival seen for pegargiminase-based chemotherapy

Greater incidence of grade 3 or higher adverse events from any cause seen in combination group versus monotherapy

Improvement in overall survival seen for patients receiving cisplatin or carboplatin with pemetrexed

More patients taking alectinib with low-fat yogurt do not reach the exposure threshold of 435 ng/mL

In phase 2 trial, overall survival longer with combo treatment compared with investigator's choice for standard of care in advanced NSCLC